Phase 2 study of Innovative Stereotactic Body RadioTherapy targeting PArtial Tumor HYpoxic (SBRT-PATHY) Clonogenic Cells in Unresectable Bulky Non-Small Cell Lung Cancer: Profound Non-Targeted Effects by Sparing Peri-Tumoral Immune Microenvironment

被引：0
|
作者：
Tubin, S. [1 ]
机构：
[1] KABEG Klinikum Klagenfurt, Strahlentherapie, Klagenfurt, Austria
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2020年 / 196卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OE10
引用
收藏
页码：300 / 300
页数：1
相关论文
共 3 条
  • [1] Mono-institutional phase 2 study of innovative Stereotactic Body RadioTherapy targeting PArtial Tumor HYpoxic (SBRT-PATHY) clonogenic cells in unresectable bulky non-small cell lung cancer: profound non-targeted effects by sparing peri-tumoral immune microenvironment
    Slavisa Tubin
    Mohammad K. Khan
    Gerardo Salerno
    Waleed F. Mourad
    Weisi Yan
    Branislav Jeremic
    Radiation Oncology, 14
  • [2] Mono-institutional phase 2 study of innovative Stereotactic Body RadioTherapy targeting PArtial Tumor HYpoxic (SBRT-PATHY) clonogenic cells in unresectable bulky non-small cell lung cancer: profound non-targeted effects by sparing peri-tumoral immune microenvironment
    Tubin, Slavisa
    Khan, Mohammad K.
    Salerno, Gerardo
    Mourad, Waleed F.
    Yan, Weisi
    Jeremic, Branislav
    RADIATION ONCOLOGY, 2019, 14 (01)
  • [3] A PHASE 2 STUDY OF DURVALUMAB COMBINED WITH CHEMOTHERAPY AND STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN PATIENTS WITH OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) (SABRCURE TRIAL)
    Chen, Ming
    Ma, Honglian
    Du, Xianghui
    Xu, Yujin
    Ji, Yongling
    Song, Zhengbo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A729 - A729
1